x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230602
| Product Information | |
|---|---|
| CAS No. | 22252-07-9 |
| Synonyms | 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC |
| Formula | C26H50NO7P |
| Molecular Weight | 519.65 |
| Target | Estrogen Receptor/ERR |
| Product Description | Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 96% |
| Shipping | Shipped on dry ice. |
| Storage | -20 °C, stored under nitrogen *In solvent : -80 °C, 6 months; -20 °C, 1 month (stored under nitrogen) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
